National Taiwan University Hospital: Carcinoma trials

The registry lists 57 Carcinoma studies with National Taiwan University Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 19Phase 3 3No phase 33(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of RecurrenceNot yet recruitingNCT06237946
• A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular CarcinomaNot yet recruitingNCT05752890
• Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC PatientsRecruitingNCT05743504Phase 1/2
• Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.Not yet recruitingNCT05286320Phase 1/2
• Urine Omics Predicting IO Therapy Responses in mRCC PatientsRecruitingNCT04712305
• Urine Omics Predicting IO Therapy Responses in mUC PatientsRecruitingNCT04641936
• Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal CarcinomatosisRecruitingNCT04547725Not applicable
• Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in SituRecruitingNCT04046159Phase 3
• MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular CarcinomaNot yet recruitingNCT02448056
• Peri-operative Vitamin D Therapy for HepatectomyStatus unknownNCT05650151Not applicable
• A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma PatientsStatus unknownNCT05281926Phase 1
• Neo-NTP-CRT for Locally Advanced ESCCStatus unknownNCT05130684Phase 2
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
• Myeloid-derived Suppressor Cells (MDSCs) in OSCC PatientsStatus unknownNCT04387682Not applicable
• P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaStatus unknownNCT04233840Phase 1/2
• Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1
• Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT04183088Phase 2
• The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03800953Phase 2
• Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCCStatus unknownNCT03623737Phase 2/3
• Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in TaiwanStatus unknownNCT03283956
• HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCCStatus unknownNCT03020342
• Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCCStatus unknownNCT02812641Phase 2
• Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular CarcinomaStatus unknownNCT02550613
• Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical PrognosisStatus unknownNCT02401763
• BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial CarcinomaStatus unknownNCT02278978Phase 2
• To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular CarcinomaStatus unknownNCT02074202Phase 3
• 3T MRI to Predict TACE Response of HCCStatus unknownNCT02070822
• The Role of microRNA-29b in the Oral Squamous Cell CarcinomaStatus unknownNCT02009852
• EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma CellsStatus unknownNCT01993966
• The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial CarcinomaStatus unknownNCT01968928
• PLA for HCC and Esophageal ca SerumStatus unknownNCT01957241
• Circulating Tumor Cells for Hepatocellular CarcinomaStatus unknownNCT01930383
• Lenalidomide as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01545804Phase 2
• The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular CarcinomaStatus unknownNCT01380392
• Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT01377298Phase 2
• Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional TherapyStatus unknownNCT01281683
• Axitinib as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01273662Phase 2
• Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial HyperplasiaStatus unknownNCT01273636
• Different Genetic Features Associated With Hepatic CarcinogenesisStatus unknownNCT01247506
• A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)Status unknownNCT00960167Phase 1
• Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in TaiwanStatus unknownNCT00867633
• Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial CarcinomaStatus unknownNCT00854464
• The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation TherapyStatus unknownNCT00751543Not applicable
• UFUR Plus Thalidomide for Advanced Hepatocellular CarcinomaCompletedNCT00519688Phase 2
• Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)CompletedNCT00464919Phase 2
• The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown PrimaryStatus unknownNCT00302588
• Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCCCompletedNCT00173862Phase 2
• PTEN and IGFBP-3 Correlation in Ovarian Carcinoma InvasionWithdrawnNCT00173407Not applicable
• Genetic Studies in Liver Cancer PatientsStatus unknownNCT00172640
• Chemoprevention Trial for Uremia-Associated Urothelial CarcinomaWithdrawnNCT00172367Phase 2
• Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular CarcinomaStatus unknownNCT00155272Phase 1/2
• Molecular Mechanism of Nasopharyngeal CarcinomaStatus unknownNCT00155181
• Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular CarcinomaStatus unknownNCT00155103
• IGFBP-3 in Ovarian Cancer InvasionStatus unknownNCT00154986Not applicable
• A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00154817Phase 2
• Searching for the Liver Cancer-Related BiomarkersStatus unknownNCT00154544
• Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDIStatus unknownNCT00154531